Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

18 results about "Mannosidase" patented technology

Mannosidase is an enzyme which hydrolyses mannose.

Cell preparation mycoplasma detection method and kit thereof

The invention provides a method for detecting mycoplasma of a cell preparation. The method comprises the following steps: (1) incubating quantitative cell preparation samples to be detected, quantitative alpha-mannosidase and quantitative 6-chloro-3-indole-a-D-mannoside in a buffer solution with the pH value of 3.5-4.5 at 36-38 DEG C for 15-60 minutes; (2) adding a quantitative swainsonine inhibitor into the reaction system to terminate the reaction when the incubation is finished; and (3) detecting the light absorption signal intensity of the liquid treated in the step (2) at 505-515nm. The invention provides simultaneous detection of extracellular and intracellular mycoplasma contents of a cell preparation for the first time, the extracellular mycoplasma concentration A and the intracellular mycoplasma concentration B are obtained, and the ratio of the mycoplasma concentration A to the mycoplasma concentration B is marked as an environmental influence coefficient alpha; the smaller the alpha is, the smaller the influence of the extracellular environment of the cell preparation on the cell infection in the cell preparation is.
Owner:GUANGZHOU SHAAI BIOTECHNOLOGY CO LTD

Efficient extraction and purification process of icariin in plateau herba epimedii and application of icariin

The invention relates to the technical field of traditional Chinese medicine effective component extraction, and provides an efficient extraction and purification process and application of icariin in plateau herba epimedii, the efficient extraction and purification process of icariin in plateau herba epimedii comprises the following steps: S1, epimedium leaves are crushed and sieved to obtain epimedium powder; s2, adding an ethanol solution into the herba epimedii powder, then adding a compound enzyme, performing ultrasonic treatment, inactivating the enzyme, performing suction filtration, and collecting filtrate to obtain an icariin crude extract; s3, diluting the crude icariin extract, adjusting the pH value to 5-6, carrying out chromatographic purification and elution, and collecting the eluate; s4, performing vacuum concentration on the eluent, and performing spray drying to obtain a pure icariin product; the compound enzyme comprises cellulase, pectinase and alpha-mannosidase in a mass ratio of 3: 1: (0.2-1.0). By means of the technical scheme, the problem that in the prior art, the extraction rate of icariin in plateau herba epimedii is low is solved.
Owner:QINGHAI HUAXIA AGRI SCI & TECH CO LTD

Influenza vaccine comprising whole virus, split virus or virus like particles with partially glycosylated surface viral glycoprotein

PCT designated stage expiredWO2025111005A1SsRNA viruses negative-senseViral antigen ingredientsViral glycoproteinEmbryonated chicken egg
The present invention provides a vaccine composition comprising a therapeutically effective amount of whole influenza virus, split influenza virus, virus like particle (VLP) or a combination thereof wherein one or more surface viral glycoproteins of the whole influenza virus, split influenza virus or VLP is partially glycosylated; and wherein the whole influenza virus and the split influenza virus has been attenuated or inactivated. The present invention also provides a method of preparation of the vaccine comprising the steps of injecting working virus seed with an inhibitor of the mannosidase into embryonated chicken egg to inoculate the embryonated chicken egg; incubating the inoculated embryonated chicken egg to propagate the working vims; harvesting allantonic fluids from the inoculated embryonated chicken egg; concentrating and clarifying the harvested allantonic fluids; purifying the concentrated and clarified allantonic fluids using sucrose density centrifugation; applying deglycosylation enzyme to the purified allantonic fluid to partially glycosylate viral surface glycoprotein of the propagated vims within the purified allantonic fluid; removing deglycosylation enzyme from whole vims with partially glycosylated viral surface glycoprotein; and inactivating the vims. The present invention further provides a method of treatment for prevention of influenza infection comprising the step of administering any embodiment of the vaccine of the present invention to a subject.
Owner:RUENHUEI BIOPHARMACEUTICALS INC +1

Glycoengineering of THERMOTHEMYCES HETEROTHALLICA

In particular, provided are Thermothelomyces thermophila (Myceliomyces thermophila) genetically modified to produce glycoproteins having N-glycans of mammalian proteins, in particular human, companion animal and other animal proteins, which comprise a deletion or disruption of the alg3 gene, the expression of ER-targeted mannosidase 1 (alpha-1, 2-mannosidase), and the expression of the ER-targeted glucosidase 2 alpha subunit. The Th.hetero-thalica can further comprise a heterologous GlcNAc transferase 1 (GNT1), a GlcNAc transferase 2 (GNT2), an STT3 subunit of a heterologous oligoglycosyl transferase, and a galactosyl transferase, and can be used for preparing a transferase product.
Owner:DYADIC INTERNATIONAL INC

I-type alpha-mannosidase and application thereof

PendingCN121160672ABacteriaHydrolasesHeterologousGlycoprotein structure
The invention provides I-type alpha-mannosidase, an expression vector, and a transgenic cell line and host bacteria containing the expression vector. According to the invention, the function of the SlMNSI1 gene related to tomato protein N-glycosylation is cloned and verified for the first time, heterologous active expression of the SlMNSI1 gene is realized, and the recombinant protein can utilize a high mannose type N-sugar chain (H8N2F0X0) as a substrate to efficiently catalyze and shear mannose residues connected with alpha-1, 2-at the tail end of the recombinant protein so as to generate a Man5GlcNAc2 (H5N2F0X0) product. The invention also provides the SlMNSI1 gene and an encoding protein thereof, an expression vector containing the SlMNSI1 nucleotide sequence, and application of a transgenic cell line and host bacteria containing the expression vector in N-carbohydrate chain modification and glycosylation engineering. The invention further provides application of the expression vector and a transgenic cell line or host bacteria containing the vector in glycoprotein structure optimization, drug research and development and metabolic engineering.
Owner:ZHEJIANG UNIV

Methods of Manufacturing Alpha-1 Antitrypsin Compositions For Treatment of Disease Disorders

A method for producing recombinant glycoproteins, focusing on human alpha-1 antitrypsin (AAT), using Pichia Pastoris yeast. Involves expressing the AAT polypeptide in an engineered yeast strain lacking the wild-type OCH1 gene and containing either a mutant OCH1 gene or a mannosidase gene. After expression, the AAT-containing supernatant is isolated, and the non-natively glycosylated AAT is purified to achieve a substantially homogeneous population of N-glycans. The purification process aims to limit the presence of specific glycan structures to less than 20%. Throughout the manufacturing process, including isolation and purification, the vitality of the Pichia Pastoris yeast strain is carefully maintained. This method offers precise control over glycosylation patterns, ensuring the production of recombinant glycoproteins with tailored characteristics for diverse biotechnological and therapeutic applications.
Owner:LEZDEY DARREN +2

N-glycosylation mutants of type I alpha-mannosidase and application of N-glycosylation mutants

PendingCN121294403AHydrolasesFermentationGolgi componentNicotiana tabacum
The invention relates to a group of N-glycosylation mutants of type I alpha-mannosidase and application of the N-glycosylation mutants. According to the invention, N-glycosylation modification of tomato-sourced I-type alpha-mannosidase SlMNSI1 at amino acid residues N288 and N334 is analyzed for the first time, and the modification sites are located in a conserved structural domain of a GH47 glycoside hydrolase family. N288A, N334A and N288A / N334A mutants are further constructed, and the N288A, N334A and N288A / N334A mutants are transiently expressed in mesophyll cells of the nicotiana benthamiana. Positioning analysis shows that the mutant can still be partially positioned in the Golgi apparatus, but protein aggregates appear and are transferred to the periphery of the endoplasmic reticulum. Protein stability detection shows that the N-glycosylation modified mutant is obviously accelerated to degrade after being treated by the cycloheximide, which indicates that the glycosylation modification of the N288 and N334 sites has an important effect on the stability and subcellular localization of the SlMNSI1. The functional characteristics of key glycosylation sites of the type I alpha-mannosidase are disclosed for the first time, a group of N-glycosylation mutants with structure and function differences are provided, and the N-glycosylation mutants can be used as important tools for researching plant glycosylation regulation, protein engineering modification and gene function identification and have wide application prospects.
Owner:ZHEJIANG UNIV

α-mannosidase with plant immune activation function and application thereof

The present invention discloses an α-mannosidase and application with activating plant immunity, wherein the α-mannosidase is a protein whose amino acid sequence is as shown in SEQ ID NO.2, or a fusion protein as shown in SEQ ID NO.2, a protein with 85% or more homology and the same function. The α-mannosidase of the present invention can effectively stimulate and induce immune responses such as host active oxygen burst, callose accumulation and upregulation of immune pathway-related genes, and can also keep the host in a "preparatory" state, can enhance the host's disease resistance, effectively and energy-savingly resist subsequent pathogen infection, prevent or reduce the occurrence of diseases, can be used as an elicitor for inducing plant immunity during plant-microorganism interaction, and can therefore be used as an effective ingredient of a plant immune inducer, widely used to activate and enhance the immune activation ability of plants, and has broad application prospects in agricultural production.
Owner:HENAN JUBANG BIOLOGICAL PHARM CO LTD

Methods of determining glycan pairing content

PCT designated stageWO2026090253A1Biological material analysisBiological testingFucosylationHigh mannose
Methods of determining glycan pairing content of a protein composition are provided. In exemplary embodiments, the method comprises (a) treating a sample of the protein composition with (i) a mannosidase and (ii) a β1-4 endoglycosidase, to produce a mixture of components of the protein, wherein at least some of the components comprises one or more digested glycan structures; and (b) separating the components of the mixture based on molecular weight; and (c) quantifying the abundance of glycan pairs, optionally, quantifying (i) paired afucosylated glycans, (ii) unpaired afucosylated glycans, (iii) paired high mannose glycans, and / or (iv) unpaired high mannose glycans, of the mixture. In exemplary aspects, the method comprises quantifying the relative unpaired afucosylated (AF) glycan content and / or relative unpaired high mannose (HM) glycan content of the mixture.
Owner:AMGEN INC

Application of mannosidase alpha2B enzyme gene MAN2B1 inhibitor in inhibiting physiological behaviors of neurons

The invention discloses an application of a mannosidase alpha2B enzyme gene MAN2B1 inhibitor in inhibiting physiological behaviors of neurons. The MAN2B1 inhibitor inhibits substance metabolism, adhesion, spreading and protrusion branch growth of the neurons by inhibiting expression of mannosidase alpha2B enzymes. The invention proposes and verifies that the mannosidase alpha2B enzyme gene MAN2B1 inhibitor can effectively inhibit the physiological behaviors of neurons for the first time, and provides a new direction for research and development of drugs for treating diseases caused by excessive growth of neuronal axons of a peripheral or central nervous system.
Owner:NANTONG UNIV

Expression system for glycoengineered antigens

The present invention relates to an expression system for the extracellular production of recombinant tri-fucosylated N-glycoproteins in insect cells. The invention also relates to an expression cassette comprising a glyco-module comprising polynucleotide sequences of a nematode galactosyltransferase, fucosyltransferase, and mannosidase; and a polynucleotide sequence encoding one or more tri-fucosylated N-glycoproteins derived from a nematode; a recombinant baculovirus comprising said expression cassette, a method for producing said tri-fucosylated N-glycoproteins in transfected insect cells, and a transfected insect cell. The invention also relates to an immunological composition comprising said tri-fucosylated N-glycoproteins, which can be administered to ruminants to induce protective anti-nematode immunity.
Owner:VETERINARMEDIZINISCHE UNIV WIEN +2

Application of alpha-1, 2-mannose structure in preparation of liver cancer diagnosis and prognosis product

The invention belongs to the technical field of molecular biology, and relates to application of alpha-1, 2-mannose structure change in preparation of a liver cancer diagnosis or prognosis product, research is carried out through the effect of alpha-1, 2-mannosidase MAN1C1 in liver cancer, and the result shows that the expression quantity of the MAN1C1 in liver cancer tissue is obviously lower than that in para-carcinoma tissue; low expression of MAN1C1 is related to poor prognosis of the liver cancer patient; lectin MVN detection proves that alpha-1, 2-mannose structures of N-sugar chains in liver cancer tissues are significantly more than paracancerous structures, and high abundance of alpha-1, 2-mannose is related to poor prognosis of liver cancer patients. Further, in-vitro cell experiments show that the survival ability of liver cancer cells is improved under the condition of nutrition deficiency after the MAN1C1 is knocked down, and in-vivo mouse tumorigenesis experiments show that the low expression of the MAN1C1 can promote the growth of tumors. Therefore, the alpha-1, 2-mannose structure can be used as a diagnostic marker for diagnosis and prognosis of liver cancer, and is suitable for liver cancer diagnosis methods such as lectin and the like and liver cancer diagnosis kits.
Owner:FUDAN UNIVERSITY

Epimedium extract for activating cell autophagy as well as preparation method and application of epimedium extract

The invention relates to a herba epimedii extract for activating cell autophagy and a preparation method and application thereof.The herba epimedii extract is prepared from specific zymophyte and compound enzyme, the content of icariside I in the herba epimedii extract is increased, and the herba epimedii extract can activate cell autophagy by up-regulating expression of lysosome mannosidase (LManV). The composition has the advantages that the autophagy flow of cells is obviously enhanced, the fusion of autophagosome and lysosome is promoted, the p62 / Ref( 2) P accumulation caused by the decline of the autophagy function is efficiently reversed, the steady state of the environment in the cells is maintained, the aging speed of the cells is delayed, the support is provided for the aging resistance of the organism from the cellular level, the improvement of the aging-related physical state and the maintenance of the vitality of the organism are helped, and the composition is safe and non-toxic to the human body.
Owner:FOSHAN GOLDEN HEALTH TECH CO LTD

Mannose functionalized supramolecular nanoparticles as well as preparation method and application thereof

The invention provides mannose functionalized supramolecular nanoparticles and a preparation method and application thereof, the nanoparticles are formed by supermolecule self-assembly of a water-soluble amphiphilic compound MaCa in a water phase, and the nanoparticles are used for targeted therapy and early diagnosis of triple negative breast cancer (TNBC). A surface mannose unit of the nanoparticle is specifically combined with a TNBC marker alpha-mannosidase 2C1, and a hydrophobic core loaded drug (such as paclitaxel) or an imaging reagent (such as DiR and MRI contrast agents). Experiments show that the enrichment amount of the particles at the tumor part is 9.3 times of that of a control group, the tumor volume disappears after the particles are treated for 7 days, and the particles have no obvious toxicity. The process is simple and convenient, and an innovative solution is provided for TNBC diagnosis and treatment integration.
Owner:WUHAN UNIV

Fluoro-polyhydroxy indolizidine compound, pharmaceutically acceptable salt and synthetic method thereof, glycosidase inhibitor and application of glycosidase inhibitor

The invention relates to the technical field of glycosidase inhibitors, and discloses a fluorinated polyhydroxy indolizidine compound and pharmaceutically acceptable salt and a synthetic method thereof, and a glycosidase inhibitor and application thereof. The compound has a chemical structure as shown in a formula (1), wherein R1 and R1'are fluorine or hydrogen; wherein R2 is hydrogen or acyl; wherein R3 and R4 are each independently hydrogen, or a combination of R3 and R4 forms a propylidene group; wherein in the formula (1) # imgabs0 #, the spatial configurations of 1, 2, 8 and 8a-site carbon atoms are respectively and independently R or S; the fluoro polyhydroxy indolizidine compound prepared by the invention can be applied to a glycosidase inhibitor, has high inhibition activity of alpha-mannosidase or inhibition activity of alpha-L-rhamnosidase, has high selectivity, and can be applied to the field of medicine preparation.
Owner:INST OF CHEM CHINESE ACAD OF SCI

A zephyranthes grandiflora powder enzymatic hydrolysate having an anticoagulant effect

This invention discloses an enzymatic hydrolysate of taro flour with anticoagulant properties. The invention uses taro flour as raw material and prepares the taro flour enzymatic hydrolysate through water extraction, alcohol precipitation, resolution, starch removal with amylase, further alcohol precipitation, further resolution, and glycosidic hydrolysis. The enzymes used are galactosidase, fucosidase, and mannosidase. The taro flour enzymatic hydrolysate prepared by this invention can delay blood clotting time and has anticoagulant properties, and can be used as a functional ingredient to make beverages and foods with anticoagulant effects.
Owner:YUNNAN HOT WORK GREAT HEALTH IND RES INST CO LTD